2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.

Bioorg Med Chem Lett

NIH Chemical Genomics Center, NIH Center for Translational Therapeutics, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, USA.

Published: November 2011

Compared to normal differentiated cells, cancer cells have altered metabolic regulation to support biosynthesis and the expression of the M2 isozyme of pyruvate kinase (PKM2) plays an important role in this anabolic metabolism. While the M1 isoform is a highly active enzyme, the alternatively spliced M2 variant is considerably less active and expressed in tumors. While the exact mechanism by which decreased pyruvate kinase activity contributes to anabolic metabolism remains unclear, it is hypothesized that activation of PKM2 to levels seen with PKM1 may promote a metabolic program that is not conducive to cell proliferation. Here we report the third chemotype in a series of PKM2 activators based on the 2-oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamide scaffold. The synthesis, structure activity relationships, selectivity and notable physiochemical properties are described.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224553PMC
http://dx.doi.org/10.1016/j.bmcl.2011.08.114DOI Listing

Publication Analysis

Top Keywords

pyruvate kinase
12
anabolic metabolism
8
2-oxo-n-aryl-1234-tetrahydroquinoline-6-sulfonamides activators
4
activators tumor
4
tumor cell
4
cell specific
4
specific isoform
4
isoform pyruvate
4
kinase compared
4
compared normal
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!